CagriSema vs Survodutide
A side-by-side research comparison of CagriSema and Survodutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CagriSema | Survodutide |
|---|---|---|
| Full name | CagriSema (Cagrilintide + Semaglutide) | Survodutide (Dual GLP-1/Glucagon Agonist) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | Phase 3 Clinical Trial |
| Mechanism | Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression. | Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. |
| Molecular weight | Combination product | 4,500 Da (approximate) |
| Half-life | 7 days (both components) | 5-7 days |
| Bioavailability | High (SubQ) | High (SubQ) |
| Typical dose | Cagrilintide 2.4mg + Semaglutide 2.4mg | 0.6-6.0 mg |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous | Subcutaneous |
CagriSema reported benefits
- Enhanced weight loss vs monotherapy
- Dual appetite suppression
- Convenient single injection
- Improved metabolic parameters
- Potential 20-25% weight loss
Survodutide reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Related comparisons
Research and educational reference only. Not medical advice.